US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Good Neighbor Pharmacy

Reason MICROBIAL CONTAMINATION OF NON-STERILE PRODUCTS - Presence of Acetobacter nitrogenifigens bacteria.

Pharma Nobis LLC NDC 46122-741-38 D-0227-2024
Class II · Moderate risk Terminated

Desloratadine Tablets USP 5mg a) 100 count

Reason CGMP Deviations: N-Nitroso Desloratadine impurity result exceeded the acceptable intake limit.

Lupin Pharmaceuticals Inc. NDC 68180-153-01 D-0221-2024
Class II · Moderate risk Terminated

Tacrolimus Capsules

Reason Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk Ongoing

Selenium Sulfide 2.25% Shampoo

Reason CGMP Deviations: Stability data does not support expiry date.

Private Label Partners, Inc. NDC 42582-900-06 D-0152-2024
Class II · Moderate risk Ongoing

Sertraline Tablets

Reason CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk Ongoing

Nystatin 150 Mu

Reason Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Fagron, Inc NDC 51552-0041-1 D-0157-2024
Class II · Moderate risk Ongoing

Nystatin 2 Bu

Reason Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Fagron, Inc NDC 51552-0041-4 D-0156-2024
Class II · Moderate risk Ongoing

Nystatin 500 Mu

Reason Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Fagron, Inc NDC 51552-0041-3 D-0155-2024
Class II · Moderate risk Ongoing

Nystatin 5bu

Reason Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Fagron, Inc NDC 51552-0041-5 D-0154-2024
Class II · Moderate risk Terminated

Liothyronine Sodium Tablets

Reason Failed Impurities/Degradation Specifications

Sun Pharmaceutical Industries INC NDC 62756-589-88 D-0150-2024
Class II · Moderate risk Completed

ROPivacaine HCl 0.2% PF in Sodium Chloride 1

Reason STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigation, they determine the source of the issue was with the bag manufacturer who released bags Lot # 134142-001A which had failed internal QC tests for leaks.

STAQ Pharma, Inc. NDC 73177-0109-26 D-0147-2024
Class II · Moderate risk Terminated

B-Complex

Reason Presence of Particulate Matter.

AnazaoHealth Corporation NDC 72682-2230-3 D-0203-2024
Class II · Moderate risk Terminated

Penicillamine Tablets USP 250 mg

Reason Failed Dissolution Specifications

Lupin Pharmaceuticals Inc. NDC 70748-153-01 D-0148-2024
Class II · Moderate risk Completed

Ondansetron Injection

Reason Failed pH Specifications

Baxter Healthcare Corporation NDC 36000-012-25 D-0146-2024
Class II · Moderate risk Terminated

PAROXETINE tablets

Reason Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalling lots due to Out of specification results for the excipient Amadori Glucose adduct of Paroxetine

Golden State Medical Supply Inc. NDC 60429-737-30 D-0130-2024
Class II · Moderate risk Terminated

PAROXETINE tablets

Reason Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalling lots due to Out of specification results for the excipient Amadori Glucose adduct of Paroxetine

Golden State Medical Supply Inc. NDC 60429-735-90 D-0129-2024
Class II · Moderate risk Terminated

PAROXETINE tablets

Reason Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalling lots due to Out of specification results for the excipient Amadori Glucose adduct of Paroxetine

Golden State Medical Supply Inc. NDC 60429-734-30 D-0128-2024